Skip to main content

Main menu

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
  • Other Publications
    • www.clevelandclinic.org

User menu

  • Register
  • Log in

Search

  • Advanced search
Cleveland Clinic Journal of Medicine
  • Other Publications
    • www.clevelandclinic.org
  • Register
  • Log in
Cleveland Clinic Journal of Medicine

Advanced Search

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
Editorial

Glycemic targets in the ICU: A look back, and ahead

Keren Zhou, MD
Cleveland Clinic Journal of Medicine April 2022, 89 (4) 189-190; DOI: https://doi.org/10.3949/ccjm.89a.21127
Keren Zhou
Research Director, Department of Endocrinology, Diabetes, and Metabolism, Endocrinology and Metabolism Institute, Cleveland Clinic; Clinical Assistant Professor of Medicine, Lerner College of Medicine of Case Western Reserve University, Cleveland, OH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: [email protected]
  • Find this author on Cleveland Clinic
  • Article
  • Info & Metrics
  • PDF
Loading

Inpatient hyperglycemia is associated with significant morbidity and mortality, including in the intensive care unit (ICU). However, when it comes to optimal blood glucose targets, controversy abounds. In this issue, Alhatemi et al1 reflect on how we arrived at the current blood glucose targets and offer important insights on the future of glycemic monitoring and targets in critically ill patients.

See related article page 191

HISTORICAL INSIGHTS

While a number of studies reported the association between hyperglycemia and poorer outcomes for patients in the ICU, 2 studies in Leuven, Belgium,2,3 were the first to look at how achieving intensive glucose control affects clinical outcomes. The positive effect of glucose control on mortality and morbidity noted in those studies led to attempts to achieve even tighter glycemic control in patients in the ICU. But this movement came to a halt in 2009 with the publication of the Normoglycemia in Intensive Care Evaluation–Survival Using Glucose Algorithm Regulation (NICE-SUGAR) study,4 which demonstrated increased mortality in critically ill patients with intensive glucose control.

Alhatemi et al nicely outline the basic differences between the Leuven studies and the NICE-SUGAR study. It is worth noting that caloric intake was higher in the Leuven studies, which may have mitigated some of the hypoglycemia seen in the NICE-SUGAR study. Furthermore, there was less overlap in glucose values between the intensive-control and conventional-control groups in the Leuven studies than in the NICE-SUGAR study, which may have enhanced the detection of outcome differences in the Leuven studies.5

Ultimately, the divergent findings of these trials serve to highlight a very important point—that there may not be a one-size-fits-all approach to glycemic targets.

THE IMPORTANCE OF CONTEXT

The question that naturally arises then is whether there actually is a group of patients in the ICU who benefit from an intensive glucose control strategy? The answer appears to be that critically ill patients with well-controlled diabetes mellitus or without preexisting diabetes benefit from a more intensive glucose control strategy while, conversely, rapidly lowering glucose values in patients with poorer preadmission diabetes mellitus control is actually deleterious.

Egi et al6 examined how preexisting hyperglycemia influenced the association between glycemia and mortality in a study of 415 critically ill patients with diabetes. They found that in patients with higher preadmission hemoglobin A1c (> 7%), the higher the level of acute glycemia during the ICU stay, the lower the rate of in-hospital mortality as opposed to patients in the ICU with lower preadmission hemoglobin A1c levels (< 7%).

Naraba et al7 considered blood glucose target time-in-range (TIR) and 28-day mortality in 1,230 critically ill patients. In patients with a preadmission hemoglobin A1c < 6.5%, a lower TIR of 70 to 180 mg/dL was associated with increased mortality, an association not seen in patients with a hemoglobin A1c ≥ 6.5%.

While these trials suggest an interaction between preadmission glycemic state and response to intensive glucose control in patients in the ICU, the Glycemic Stability During the Intraoperative Period Among Patients With DM Undergoing CABG Surgery (GLUCO-CABG) study8 demonstrated this principle in prospective randomized fashion. Overall, intensive glucose control did not improve outcomes after cardiac surgery, but subsequent subgroup analysis revealed a lower rate of complications in patients without diabetes but with intensive glucose control. The physiologic basis for this is not clear, although one might postulate that there is a relative neuroglycopenia when patients with suboptimal glycemic control receive intensive glucose control.9

CONTINUOUS GLUCOSE MONITORING: THE FUTURE?

As Alhatemi et al1 point out, increasing attention is being paid to TIR and glycemic variability as targets for intervention for patients in the ICU. The studies done thus far on measurements of glycemic control have typically been extrapolated to TIR and glycemic variability from point-of-care glucose readings as opposed to using true continuous glucose monitoring.

An approach with the potential to significantly alter inpatient glycemic management is the use of current outpatient continuous glucose monitoring devices in the inpatient setting. Currently, 2 devices are approved for use in the hospital (GlucoScout and OptiScanner 5000).10 However, their availability in ICUs is limited, and they require a dedicated central or peripheral access for blood sampling. However, the COVID-19 pandemic has opened the doors to the testing and use of outpatient glucose monitoring devices in the hospital, showing that even in the ICU, outpatient devices can be used, although calibration is needed.11,12 This allows us to envision, in addition to telemetry for cardiac monitoring, the use of glucose tracings with alarms to monitor for hyperglycemia and hypoglycemia in hospital inpatients.

Much work still needs to be done to better understand the nuances of glycemic targets in critically ill patients, and to learn how to take advantage of evolving technology to improve appropriate glycemic control in the ICU.

DISCLOSURES

The author reports no relevant financial relationships which, in the context of her contributions, could be perceived as a potential conflict of interest.

  • Copyright © 2022 The Cleveland Clinic Foundation. All Rights Reserved.

REFERENCES

  1. ↵
    1. Alhatemi G,
    2. Aldiwani H,
    3. Alhatemi R,
    4. Hussein M,
    5. Mahdai S,
    6. Seyoum B
    . Glycemic control in the critically ill: Less is more. Cleve Clin J Med 2022; 89(4):191–199. doi:10.3949/ccjm.89a.20171
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. van den Berghe G,
    2. Wouters P,
    3. Weekers F, et al
    . Intensive insulin therapy in critically ill patients. N Engl J Med 2001; 345(19):1359–1367. doi:10.1056/NEJMoa011300
    OpenUrlCrossRefPubMed
  3. ↵
    1. Van den Berghe G,
    2. Wilmer A,
    3. Hermans G, et al
    . Intensive insulin therapy in the medical ICU. N Engl J Med 2006; 354(5):449–461. doi:10.1056/NEJMoa052521
    OpenUrlCrossRefPubMed
  4. ↵
    1. NICE-SUGAR Study Investigators,
    2. Finfer S,
    3. Chittock DR,
    4. Li Y, et al
    . Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009; 360(13):1283–1297. doi:10.1056/NEJMoa0810625
    OpenUrlCrossRefPubMed
  5. ↵
    1. Van den Berghe G,
    2. Schetz M,
    3. Vlasselaers D, et al
    . Clinical review: intensive insulin therapy in critically ill patients: NICE-SUGAR or Leuven blood glucose target? J Clin Endocrinol Metab 2009; 94(9): 3163–3170. doi:10.1210/jc.2009-0663
    OpenUrlCrossRefPubMed
  6. ↵
    1. Egi M,
    2. Bellomo R,
    3. Stachowski E, et al
    . The interaction of chronic and acute glycemia with mortality in critically ill patients with diabetes. Crit Care Med 2011; 39(1):105–111. doi:10.1097/CCM.0b013e3181feb5ea
    OpenUrlCrossRefPubMed
  7. ↵
    1. Naraba H,
    2. Goto T,
    3. Shirakawa T, et al
    . Time in blood glucose range 70 to 180 mg/dL and survival rate in critically ill patients: a retrospective cohort study. PLoS One 2021; 16(5):e0252158. Published 2021 May 27. doi:10.1371/journal.pone.0252158
    OpenUrlCrossRef
  8. ↵
    1. Umpierrez G,
    2. Cardona S,
    3. Pasquel F, et al
    . Randomized controlled trial of intensive versus conservative glucose control in patients undergoing coronary artery bypass graft surgery: GLUCO-CABG trial. Diabetes Care 2015; 38(9):1665–1672. doi:10.2337/dc15-0303
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Schlenk F,
    2. Graetz D,
    3. Nagel A,
    4. Schmidt M,
    5. Sarrafzadeh AS
    . Insulin-related decrease in cerebral glucose despite normoglycemia in aneurysmal subarachnoid hemorrhage. Crit Care 2008; 12(1):R9. doi:10.1186/cc6776
    OpenUrlCrossRefPubMed
  10. ↵
    1. Pasquel FJ,
    2. Lansang MC,
    3. Dhatariya K,
    4. Umpierrez GE
    . Management of diabetes and hyperglycaemia in the hospital. Lancet Diabetes Endocrinol 2021; 9(3):174–188. doi:10.1016/S2213-8587(20)30381-8
    OpenUrlCrossRef
  11. ↵
    1. Agarwal S,
    2. Mathew J,
    3. Davis GM, et al
    . Continuous glucose monitoring in the intensive care unit during the COVID-19 pandemic. Diabetes Care 2021; 44(3):847–849. doi:10.2337/dc20-2219
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Faulds ER,
    2. Boutsicaris A,
    3. Sumner L, et al
    . Use of continuous glucose monitor in critically ill COVID-19 patients requiring insulin infusion: an observational study. J Clin Endocrinol Metab 2021; 106(10): e4007–e4016. doi:10.1210/clinem/dgab409
    OpenUrlCrossRef
PreviousNext
Back to top

In this issue

Cleveland Clinic Journal of Medicine: 89 (4)
Cleveland Clinic Journal of Medicine
Vol. 89, Issue 4
1 Apr 2022
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Complete Issue (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Cleveland Clinic Journal of Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Glycemic targets in the ICU: A look back, and ahead
(Your Name) has sent you a message from Cleveland Clinic Journal of Medicine
(Your Name) thought you would like to see the Cleveland Clinic Journal of Medicine web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Glycemic targets in the ICU: A look back, and ahead
Keren Zhou
Cleveland Clinic Journal of Medicine Apr 2022, 89 (4) 189-190; DOI: 10.3949/ccjm.89a.21127

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Glycemic targets in the ICU: A look back, and ahead
Keren Zhou
Cleveland Clinic Journal of Medicine Apr 2022, 89 (4) 189-190; DOI: 10.3949/ccjm.89a.21127
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Linkedin Share Button

Jump to section

  • Article
    • HISTORICAL INSIGHTS
    • THE IMPORTANCE OF CONTEXT
    • CONTINUOUS GLUCOSE MONITORING: THE FUTURE?
    • DISCLOSURES
    • REFERENCES
  • Info & Metrics
  • PDF

Related Articles

  • Glycemic control in the critically ill: Less is more
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • The beat goes on: Highlights from the new American and European A-fib guidelines
  • Subclinical hypothyroidism: What’s in a name?
  • Heart to heart: Progress in cardiovascular disease prevention for people living with HIV
Show more Editorial

Similar Articles

Subjects

  • Diabetes
  • Drug Therapy
  • Emergency Medicine
  • Endocrinology
  • Hospital Medicine
  • Infectious Diseases

Navigate

  • Current Issue
  • Past Issues
  • Supplements
  • Article Type
  • Specialty
  • CME/MOC Articles
  • CME/MOC Calendar
  • Media Kit

Authors & Reviewers

  • Manuscript Submission
  • Authors & Reviewers
  • Subscriptions
  • About CCJM
  • Contact Us
  • Cleveland Clinic Center for Continuing Education
  • Consult QD

Share your suggestions!

Copyright © 2025 The Cleveland Clinic Foundation. All rights reserved. The information provided is for educational purposes only. Use of this website is subject to the website terms of use and privacy policy. 

Powered by HighWire